Figure 5. BMX is upregulated in castration-resistant and abiraterone resistant PCa.

(A) Tukey’s method for a box-and-whiskers plot of normal (N=53) and tumor (N=493) RNA expression data from the prostate cancer TCGA, where the boxes depict the 25th percentile, median, and 75th percentile, and whiskers depict the lowest value and the 75th percentile + 1.5 times the interquartile range. Dots depict outlier values greater than the 75th percentile + 1.5 times the interquartile range. (B) Box-and-whiskers plots for three metastatic CRPC RNA-seq data sets. For BMX expression, whiskers depict the 10th to 90th percentiles, while open circles depict outlier values outside the 10th and 90th percentiles. For all other genes, whiskers depict the minimum and maximum values. (C) VCaP xenografts were biopsied at three stages: androgen-dependent tumor (AD), 4 days after castration (post-cast), and castration-resistant relapsed tumor (CRPC). mRNAs were extracted from the biopsies of tumors and analyzed on Agilent microarrays. BMX expression is shown by heatmap (upper panel) and validated by qRT-PCR analysis (bottom panel). (D) Representative VCaP xenograft biopsied at different stages was immunostained for pYpY. (E) Castration resistant VCaP xenograft bearing mice were treated with abiraterone (i.p. 1 mg/day) for the first week and then 2 mg/day until progression. BMX in pre-abiraterone biopsies versus at progression were analyzed for BMX mRNA expression by qRT-PCR. (F) BMX Affymetrix expression prior to therapy (control), after 7 days of abiraterone (d7), or at relapse on abiraterone or after castration (end of study, EOS) in LuCaP PDX models (41).